These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Tian J; Avalos AM; Mao SY; Chen B; Senthil K; Wu H; Parroche P; Drabic S; Golenbock D; Sirois C; Hua J; An LL; Audoly L; La Rosa G; Bierhaus A; Naworth P; Marshak-Rothstein A; Crow MK; Fitzgerald KA; Latz E; Kiener PA; Coyle AJ Nat Immunol; 2007 May; 8(5):487-96. PubMed ID: 17417641 [TBL] [Abstract][Full Text] [Related]
10. Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus. Lindau D; Rönnefarth V; Erbacher A; Rammensee HG; Decker P Eur J Immunol; 2011 Mar; 41(3):669-81. PubMed ID: 21287547 [TBL] [Abstract][Full Text] [Related]
11. Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides. Lenert P; Goeken A; Handwerger BS; Ashman RF J Clin Immunol; 2003 May; 23(3):202-13. PubMed ID: 12797542 [TBL] [Abstract][Full Text] [Related]
12. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Nakano S; Morimoto S; Suzuki J; Nozawa K; Amano H; Tokano Y; Takasaki Y Rheumatology (Oxford); 2008 Feb; 47(2):145-9. PubMed ID: 18160420 [TBL] [Abstract][Full Text] [Related]
14. Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. Yasuda K; Richez C; Uccellini MB; Richards RJ; Bonegio RG; Akira S; Monestier M; Corley RB; Viglianti GA; Marshak-Rothstein A; Rifkin IR J Immunol; 2009 Sep; 183(5):3109-17. PubMed ID: 19648272 [TBL] [Abstract][Full Text] [Related]
15. B-cell receptor for antigen modulates B-cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus. Goeken JA; Layer T; Fleenor S; Laccheo M; Lenert P Lupus; 2010 Oct; 19(11):1290-301. PubMed ID: 20605877 [TBL] [Abstract][Full Text] [Related]
16. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371 [TBL] [Abstract][Full Text] [Related]
17. Could DNA-reactive B lymphocytes be activated through HIV-1 DNA-stimulation involving BCR/TLR-9 pathway to yield antibodies targeting viral DNA? Norelli S Med Hypotheses; 2014 Dec; 83(6):659-63. PubMed ID: 25441838 [TBL] [Abstract][Full Text] [Related]
18. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481 [TBL] [Abstract][Full Text] [Related]
19. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. Patole PS; Gröne HJ; Segerer S; Ciubar R; Belemezova E; Henger A; Kretzler M; Schlöndorff D; Anders HJ J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251 [TBL] [Abstract][Full Text] [Related]
20. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Meyers JA; Mangini AJ; Nagai T; Roff CF; Sehy D; van Seventer GA; van Seventer JM Cytokine; 2006 Sep; 35(5-6):235-46. PubMed ID: 17052915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]